Article
Sigmoid colon metastasis from hepatocellular carcinoma.
Department of Internal Medicine, University of Ulsan College of Medicine, Seoul, Korea.
The Korean Journal of Hepatology
12/2010;
16(4):397-400.
DOI:10.3350/kjhep.2010.16.4.397
pp.397-400
Source: PubMed
- Citations (16)
-
Cited In (0)
-
Article: Primary liver cancer: worldwide incidence and trends.
[show abstract] [hide abstract]
ABSTRACT: Estimates from the year 2000 indicate that liver cancer remains the fifth most common malignancy in men and the eighth in women worldwide. The number of new cases is estimated to be 564,000 per year, including 398,000 in men and 166,000 in women. In high-risk countries, liver cancer can arise before the age of 20 years, whereas, in countries at low risk, liver cancer is rare before the age of 50 years. Rates of liver cancer in men are typically 2 to 4 times higher than in women. The incidence of primary liver cancer is increasing in several developed countries, including the United States, and the increase will likely continue for some decades. The trend is a result of a cohort effect related to infection with hepatitis B and C viruses, the incidence of which peaked in the 1950s to 1980s. In selected areas of some developing countries, the incidence of primary liver cancer has decreased, possibly as a result of the introduction of hepatitis B virus vaccine. The geographic variability in incidence of primary liver cancer is largely explained by the distribution and the natural history of the hepatitis B and C viruses. The attributable risk estimates for the combined effects of these infections account for well over 80% of liver cancer cases worldwide. Primary liver cancer is the first human cancer largely amenable to prevention using hepatitis B virus vaccines and screening of blood and blood products for hepatitis B and C viruses.Gastroenterology 12/2004; 127(5 Suppl 1):S5-S16. · 11.68 Impact Factor -
Article: Hepatocellular carcinoma.
[show abstract] [hide abstract]
ABSTRACT: Hepatocellular carcinoma (HCC) is the fifth most common cause of cancer, and its incidence is increasing worldwide because of the dissemination of hepatitis B and C virus infection. Patients with cirrhosis are at the highest risk and should be monitored every 6 months. Surveillance can lead to diagnosis at early stages, when the tumour might be curable by resection, liver transplantation, or percutaneous treatment. In the West and Japan, these treatments can be applied to 30% of patients, and result in 5-year survival rates higher than 50%. Resection is indicated among patients who have one tumour and well-preserved liver function. Liver transplantation benefits patients who have decompensated cirrhosis and one tumour smaller than 5 cm or three nodules smaller than 3 cm, but donor shortage greatly limits its applicability. This difficulty might be overcome by living donation. Most HCC patients are diagnosed at advanced stages and receive palliative treatments, which have been assessed in the setting of 63 randomised controlled trials during the past 25 years. Meta-analysis shows that only chemoembolisation improves survival in well-selected patients with unresectable HCC.The Lancet 01/2004; 362(9399):1907-17. · 38.28 Impact Factor -
Article: Prognostic prediction and treatment strategy in hepatocellular carcinoma.
Hepatology 04/2002; 35(3):519-24. · 11.66 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed.
The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual
current impact factor.
Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence
agreement may be applicable.
Keywords
abdominal pain
anterior resection
CT scan
direct invasion
distant gastrointestinal tract
enhanced mass
HCC metastasis
Hepatocellular carcinoma
left lower quadrant
lymph nodes
main
major health problem
metastatic HCC
poor prognosis
sigmoid colon
sigmoid colon metastasis
TACE
transcatheter arterial chemoembolization
tumor cell
weakly positive